Previous 10 | Next 10 |
- GOCOVRI is now the first and only medication approved to treat OFF and dyskinesia motor complications - - Adamas to host webcast conference call today at 4:30 pm ET/1:30 pm PT - Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and deli...
After a gain of ~6.4% today, the shares of Adamas Pharmaceuticals (ADMS) was halted for trading with news pending.The news underlying the trading halt has not been specified, however, today is the FDA action date for the company’s marketing application for Gocovri (amantadine) to treat...
Adamas Pharmaceuticals (ADMS) inks settlement agreement with Zydus Pharmaceuticals resolving its ongoing litigation concerning Zydus’s Abbreviated New Drug Application ((ANDA)) seeking FDA approval to market a generic version of Gocovri (amantadine) extended-release capsules. Under the...
- Adamas grants Zydus license for generic version of GOCOVRI ® as of March 4, 2030 - Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affected by neurol...
Adamas has become much less exciting the last few years with sales of GOCOVRI slowing in its second year. They decided to give up on attempting to treat the walking speed in those with Multiple Sclerosis with GOCOVRI after lackluster results. Hope remains with a new CEO, Neil McFa...
Gainers: [[ADMS]] +13.2%. [[CTMX]] +5.6%. [[MSTR]] +4.9%. [[FARM]] +4.8%. [[NERV]] +4%.Losers: [[CATB]] -10.6%. [[PTVE]] -8%. [[MRVI]] -3.9%. [[ZI]] -3.8%. [[ICON]] -3.5%. For further details see: MSTR, ZI, ADMS and CATB among after-hours movers
Gainers: [[BBBY]] +17.7%. [[IMMP]] +15.8%. [[FHTX]] +7.6%. [[TLSA]] +6.8%. [[ADMS]] +6.8%.Losers: [[TTOO]] -20.3%. [[VIR]] -17.0%. [[GRTX]] -16.6%. [[AGIO]] -8.4%. [[WMG]] -7.7%. For further details see: BBBY, IMMP, TTOO and VIR among after-hours movers
Adamas Pharmaceuticals (ADMS) expects total revenue for Q4 to be $20.8M and $74.2M for FY 2020.Product sales of GOCOVRI is expected to be $19.8M for Q4, an increase of 21% from same quarter prior year and $71.2M for FY 2020.“I am proud of our team’s resilience, ab...
-- Total revenues expected to be $20.8 million for fourth quarter 2020 and $74.2 million for full year 2020 -- -- Product sales of GOCOVRI ® expected to be $19.8 million for fourth quarter 2020 and $71.2 million for full year 2020 -- -- Total prescriptio...
EMERYVILLE, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, Chief Executiv...
News, Short Squeeze, Breakout and More Instantly...
Adamas Pharmaceuticals Inc. Company Name:
ADMS Stock Symbol:
NASDAQ Market:
Adamas Pharmaceuticals Inc. Website:
Supernus Pharmaceuticals (NASDAQ: SUPN) recently announced that it's acquiring Adamas Pharmaceuticals (NASDAQ: ADMS) . In this Motley Fool Live video recorded on Oct. 13 , Motley Fool contributors Keith Speights and Brian Orelli discuss why Supernus' planned acq...
FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Adamas Pharmaceuticals, Inc. Announces Definitive Agreement to be Acquired by Supernus Pharmaceuticals, Inc” Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) surged ove...
Supernus Pharmaceuticals Inc ( NASDAQ: SUPN ) recently announced that it had entered a definitive contract to acquire Adamas Pharmaceuticals ( NASDAQ: ADMS ). Supernus is to purchase this company a tender offer that was worth about $8.10 per share. The aggregate was roug...